Meeting
2013 ASCO Annual Meeting
TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Emmanuel S. Antonarakis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Emmanuel S. Antonarakis , Paraskevi Giannakakou , Brian J. Kirby , Leonardo V. Nicacio , Mario A. Eisenberger , David M. Nanus , Scott T. Tagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01718353
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS5100)
DOI
10.1200/jco.2013.31.15_suppl.tps5100
Abstract #
TPS5100
Poster Bd #
43C
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2017 Genitourinary Cancers Symposium
AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.
First Author: Paraskevi Giannakakou
Poster
2015 Genitourinary Cancers Symposium
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis
Poster
2014 ASCO Annual Meeting
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Peter Petrylak